Skip to main
IQV

IQVIA Hlds (IQV) Stock Forecast & Price Target

IQVIA Hlds (IQV) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 50%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

IQVIA Holdings is well positioned to outperform because improving market conditions are translating into stronger bookings, rising win rates, and a steadily better book-to-bill backdrop, with TTM net new bookings increasing in each of the last four quarters and record NTM backlog revenue of $9.2B growing 7.5% y/y. Its two-segment model adds durability: R&DS is benefiting from solid EBP funding, faster decision timelines, and strong large-pharma engagement, while Commercial Solutions is seeing a meaningful tailwind from 20 novel drug approvals in 3Q26, the highest since 2021, which should support multi-year commercialization spend. The company’s proprietary health care data, entrenched customer relationships, and improving margin outlook also support healthy FCF and declining leverage, making it a strong candidate to capitalize on both CRO recovery and AI-driven opportunities.

Bears say

IQVIA Holdings is facing a negative outlook because its core CRO business is exposed to slower biotech VC funding, biopharma consolidation, and regulatory delays that can push out trial starts and approvals, weakening revenue visibility. Even with differentiated data assets—more than 1.2 billion patient records, ~64 petabytes of proprietary data, and ~120 billion healthcare records annually—the company still depends on flawless execution across 3,000 clinical trials worldwide, where enrollment, site selection, and talent shortages can trigger delays and reputational damage. The balance sheet also looks less resilient given higher-than-industry-average leverage, debt service and maturity risks, M&A execution risk, and ongoing threats from cybersecurity, AI disruption, and FX volatility.

IQVIA Hlds (IQV) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 50% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IQVIA Hlds (IQV) Forecast

Analysts have given IQVIA Hlds (IQV) a Buy based on their latest research and market trends.

According to 14 analysts, IQVIA Hlds (IQV) has a Buy consensus rating as of Oct 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $281.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $281.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IQVIA Hlds (IQV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.